DE68909419D1 - Arzneimittel, das einen mit einer organischen säure behandelten und in einem liposom verkapselten hydrophilen wirkstoff enthält. - Google Patents

Arzneimittel, das einen mit einer organischen säure behandelten und in einem liposom verkapselten hydrophilen wirkstoff enthält.

Info

Publication number
DE68909419D1
DE68909419D1 DE89911009T DE68909419T DE68909419D1 DE 68909419 D1 DE68909419 D1 DE 68909419D1 DE 89911009 T DE89911009 T DE 89911009T DE 68909419 T DE68909419 T DE 68909419T DE 68909419 D1 DE68909419 D1 DE 68909419D1
Authority
DE
Germany
Prior art keywords
liposome
enclosed
organic acid
active substance
product containing
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
DE89911009T
Other languages
English (en)
Other versions
DE68909419T2 (de
Inventor
Franz Legros
Claude-Pascal Leroy
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of DE68909419D1 publication Critical patent/DE68909419D1/de
Application granted granted Critical
Publication of DE68909419T2 publication Critical patent/DE68909419T2/de
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/645—Polycationic or polyanionic oligopeptides, polypeptides or polyamino acids, e.g. polylysine, polyarginine, polyglutamic acid or peptide TAT
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Liposomes

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Dispersion Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
DE89911009T 1988-10-12 1989-10-12 Arzneimittel, das einen mit einer organischen säure behandelten und in einem liposom verkapselten hydrophilen wirkstoff enthält. Expired - Fee Related DE68909419T2 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
BE8801180A BE1001869A3 (fr) 1988-10-12 1988-10-12 Procede d'encapsulation liposomiale d'antibiotiques aminoglucosidiques, en particulier de la gentamycine.
PCT/BE1989/000047 WO1990003781A1 (fr) 1988-10-12 1989-10-12 Composition pharmaceutique contenant un compose actif hydrophile, traite par un acide organique et encapsule dans un liposome

Publications (2)

Publication Number Publication Date
DE68909419D1 true DE68909419D1 (de) 1993-10-28
DE68909419T2 DE68909419T2 (de) 1994-05-11

Family

ID=3883685

Family Applications (1)

Application Number Title Priority Date Filing Date
DE89911009T Expired - Fee Related DE68909419T2 (de) 1988-10-12 1989-10-12 Arzneimittel, das einen mit einer organischen säure behandelten und in einem liposom verkapselten hydrophilen wirkstoff enthält.

Country Status (6)

Country Link
US (1) US5211955A (de)
EP (1) EP0479781B1 (de)
JP (1) JPH04504564A (de)
BE (1) BE1001869A3 (de)
DE (1) DE68909419T2 (de)
WO (1) WO1990003781A1 (de)

Families Citing this family (50)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5723147A (en) * 1987-02-23 1998-03-03 Depotech Corporation Multivesicular liposomes having a biologically active substance encapsulated therein in the presence of a hydrochloride
US5807572A (en) * 1988-02-18 1998-09-15 Depotech Corporation Multivesicular liposomes having a biologically active substance encapsulated therein in the presence of a hydrochloride
US5422120A (en) * 1988-05-30 1995-06-06 Depotech Corporation Heterovesicular liposomes
EP0661044A1 (de) * 1991-07-03 1995-07-05 NeXstar Pharmaceuticals, Inc. Arzneistoff enthaltende Liposomen
US5958449A (en) * 1992-12-02 1999-09-28 Nexstar Pharmaceuticals, Inc. Antibiotic formulation and use for bacterial infections
AU3244393A (en) * 1992-12-02 1994-06-22 Vestar, Inc. Antibiotic formulation and process
WO1994022430A1 (en) * 1993-04-02 1994-10-13 The Liposome Company, Inc. Method of producing liposomes
US5759571A (en) * 1993-05-11 1998-06-02 Nexstar Pharmaceuticals, Inc. Antibiotic formulation and use for drug resistant infections
US5455044A (en) * 1993-05-14 1995-10-03 Depotech Corporation Method for treating neurological disorders
DE9312509U1 (de) * 1993-08-20 1993-10-28 Euro Celtique Sa Präparate zur äußeren Verabreichung von antiseptischen und/oder die Wundheilung fördernden Wirkstoffen
CA2176712C (en) * 1993-11-16 2000-05-23 Mantripragada Sankaram Synthetic membrane vesicles with controlled release of encapsulated biologically active substances
DE4420727A1 (de) * 1994-06-15 1995-12-21 Rovi Gmbh Hautfreundliche wäßrige Liposomendispersionen, enthaltend alpha-Hydroxycarbonsäuren und/oder alpha-Hydroxyketosäuren in ihrer Salzform
US5993850A (en) * 1994-09-13 1999-11-30 Skyepharma Inc. Preparation of multivesicular liposomes for controlled release of encapsulated biologically active substances
US5931809A (en) * 1995-07-14 1999-08-03 Depotech Corporation Epidural administration of therapeutic compounds with sustained rate of release
US5997899A (en) 1996-10-01 1999-12-07 Skyepharma Inc. Method for producing liposomes with increased percent of compound encapsulated
US6123956A (en) * 1997-07-10 2000-09-26 Keith Baker Methods for universally distributing therapeutic agents to the brain
US6106858A (en) * 1997-09-08 2000-08-22 Skyepharma, Inc. Modulation of drug loading in multivescular liposomes
US6306432B1 (en) 1997-09-08 2001-10-23 Chiron Corporation High and low load formulations of IGF-I in multivesicular liposomes
PT1014946E (pt) * 1997-09-18 2010-07-06 Pacira Pharmaceuticals Inc COMPOSIÎES ANESTéSICAS LIPOSSOMAIS DE LIBERTAÆO SUSTENTADA
EP1030652B1 (de) * 1997-11-14 2012-04-25 Pacira Pharmaceuticals, Inc. Herstellung von multivesikulären liposomen
TW520294B (en) * 1998-01-08 2003-02-11 Res Dev Foundation Stabilization of lipid: DNA formulations during nebulization
CA2477979A1 (en) * 2002-03-05 2003-09-18 Transave, Inc. An inhalation system for treatment of intracellular infections
US7879351B2 (en) * 2002-10-29 2011-02-01 Transave, Inc. High delivery rates for lipid based drug formulations, and methods of treatment thereof
MXPA05004580A (es) * 2002-10-29 2005-07-26 Transave Inc Liberacion sostenida de anti - infecciosos.
US7718189B2 (en) 2002-10-29 2010-05-18 Transave, Inc. Sustained release of antiinfectives
US7601695B2 (en) 2003-03-10 2009-10-13 Optimer Pharmaceuticals, Inc. Antibacterial agents
AT500143A1 (de) * 2004-04-22 2005-11-15 Sanochemia Pharmazeutika Ag Cholinesterase-inhibitoren in liposomen sowie deren herstellung und verwendung
PL1962805T3 (pl) 2005-12-08 2017-01-31 Insmed Incorporated Kompozycje środków przeciwzapalnych oparte na lipidach do leczenia infekcji płucnych
US9149543B2 (en) * 2005-12-15 2015-10-06 The Trustees Of The University Of Pennsylvania Methods and models for rapid, widespread delivery of genetic material to the CNS using non-viral, cationic lipid-mediated vectors
WO2008137717A1 (en) 2007-05-04 2008-11-13 Transave, Inc. Compositions of multicationic drugs for reducing interactions with polyanionic biomolecules and methods and uses thereof
US9333214B2 (en) 2007-05-07 2016-05-10 Insmed Incorporated Method for treating pulmonary disorders with liposomal amikacin formulations
US9119783B2 (en) 2007-05-07 2015-09-01 Insmed Incorporated Method of treating pulmonary disorders with liposomal amikacin formulations
US9114081B2 (en) 2007-05-07 2015-08-25 Insmed Incorporated Methods of treating pulmonary disorders with liposomal amikacin formulations
CN101917850B (zh) 2007-10-25 2016-01-13 森普拉制药公司 大环内酯类抗菌剂的制备方法
ES2565083T3 (es) 2008-10-24 2016-03-31 Cempra Pharmaceuticals, Inc. Biodefensas usando macrólidos que contienen triazol
US9937194B1 (en) 2009-06-12 2018-04-10 Cempra Pharmaceuticals, Inc. Compounds and methods for treating inflammatory diseases
US8956600B2 (en) * 2009-08-10 2015-02-17 Taiwan Liposome Co. Ltd. Ophthalmic drug delivery system containing phospholipid and cholesterol
CN108310000A (zh) 2009-09-10 2018-07-24 森普拉制药公司 治疗疟疾、结核病和mac疾病的方法
KR20130120458A (ko) 2010-09-10 2013-11-04 셈프라 파마슈티컬스, 인크. 질환을 치료하기 위한 수소결합 형성 플루오로 케토라이드
KR20140139083A (ko) 2012-03-27 2014-12-04 셈프라 파마슈티컬스, 인크. 마크롤라이드계 항생제를 투여하기 위한 비경구 제제
KR102277921B1 (ko) 2012-05-21 2021-07-14 인스메드 인코포레이티드 폐 감염을 치료하기 위한 시스템
CA2891487A1 (en) 2012-11-29 2014-06-05 Insmed Incorporated Stabilized vancomycin formulations
JP6426696B2 (ja) 2013-03-14 2018-11-21 センプラ ファーマシューティカルズ，インコーポレイテッド 呼吸器疾患の治療のための方法および製剤
AU2014233240B2 (en) 2013-03-15 2018-08-09 Cempra Pharmaceuticals, Inc. Convergent processes for preparing macrolide antibacterial agents
PL3142643T3 (pl) 2014-05-15 2019-12-31 Insmed Incorporated Sposoby leczenia zakażeń płuc prątkami niegruźliczymi
EA201700155A1 (ru) * 2014-10-20 2017-10-31 Товарищество С Ограниченной Ответственностью "Фармацевтическая Компания "Ромат" Фармацевтическая композиция для лечения туберкулеза
WO2019191627A1 (en) 2018-03-30 2019-10-03 Insmed Incorporated Methods for continuous manufacture of liposomal drug products
US11033495B1 (en) 2021-01-22 2021-06-15 Pacira Pharmaceuticals, Inc. Manufacturing of bupivacaine multivesicular liposomes
US11278494B1 (en) 2021-01-22 2022-03-22 Pacira Pharmaceuticals, Inc. Manufacturing of bupivacaine multivesicular liposomes
US11357727B1 (en) 2021-01-22 2022-06-14 Pacira Pharmaceuticals, Inc. Manufacturing of bupivacaine multivesicular liposomes

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3959255A (en) * 1973-05-10 1976-05-25 Roussel-Uclaf Antibiotic aminoglycosides, and process of preparation
FR2263745B1 (de) * 1974-03-12 1977-12-02 Roussel Uclaf
FR2435481A1 (fr) * 1978-09-06 1980-04-04 Roussel Uclaf Nouveaux aminoglycosides derives de la desoxystreptamine et leurs sels, procede de preparation et application a titre de medicaments
US4424344A (en) * 1980-09-22 1984-01-03 Eli Lilly And Company 2-N-Acylated and 2-N-alkylated derivatives of 4-O-substituted-2-deoxystreptamine aminoglycosides and process
US4424345A (en) * 1980-09-22 1984-01-03 Eli Lilly And Company 1-N-Acylated and 1-N-alkylated derivatives of 4-O-substituted-2-deoxystreptamine aminoglycosides and process
US4468512A (en) * 1980-09-22 1984-08-28 Eli Lilly And Company 1-N-Acylated and 1-N-alkylated derivatives of 4-O-substituted-2-deoxystreptamine aminoglycosides
US4708861A (en) * 1984-02-15 1987-11-24 The Liposome Company, Inc. Liposome-gel compositions
JP2579625B2 (ja) * 1985-07-05 1997-02-05 ザ リポソ−ム カンパニ−，インコ−ポレイテツド 改良された取り込み効率を有するマルチラメラリポソ−ム
IL79114A (en) * 1985-08-07 1990-09-17 Allergan Pharma Method and composition for making liposomes
DE3751871D1 (de) * 1986-12-23 1996-09-19 Liposome Co Inc Guanidinaminoglycosid enthaltende Liposome

Also Published As

Publication number Publication date
BE1001869A3 (fr) 1990-04-03
US5211955A (en) 1993-05-18
WO1990003781A1 (fr) 1990-04-19
DE68909419T2 (de) 1994-05-11
EP0479781B1 (de) 1993-09-22
JPH04504564A (ja) 1992-08-13
EP0479781A1 (de) 1992-04-15

Similar Documents

Publication Publication Date Title
DE68909419T2 (de) Arzneimittel, das einen mit einer organischen säure behandelten und in einem liposom verkapselten hydrophilen wirkstoff enthält.
DE3671367D1 (de) Arzneistoffadsorbate und deren herstellung.
ATE111452T1 (de) Tetrahydronaphthalin- und indanderivate, deren herstellung und verwendung für pharmazeutische präparate.
DE68924026D1 (de) Biosensor und dessen herstellung.
DE3784027D1 (de) Absorbierende produkte und deren herstellung.
DE3782315D1 (de) Absorbierende produkte und deren herstellung.
NO874873D0 (no) Innretning for autoadministrering av fysiologisk aktive stoffer.
DK725888D0 (da) Overtrukne aktive stoffer
DE3882848D1 (de) Kosmetikbasiszubereitung mit arzneimitteleigenschaften.
DE3884891D1 (de) Aktive Matrixzelle und deren Herstellungsverfahren.
DE68909970T2 (de) Hautbehandlungsmittel.
NO881113D0 (no) Hudpleiepreparater.
DE3879111D1 (de) Pharmazeutische kautablette mit geschmaksmaskierung.
AU2578488A (en) A product, cosmetic sunscreen product, and a method for introducing an active substance into the skin
IT7821193A0 (it) Metodo per la preparzione di microgranuli gastroresistenti ed enterosolubili di sostanze farmaceutiche, in particolare di sostanze proteiche e microgranuli preparati con detto metodo.
DE68902300T2 (de) Pharmazeutische loesung enthaltend salbutamol und cromoglycinsaeure.
DE3782480D1 (de) Gefriergetrocknete arzneimittel mit phenylchinolincarbonsaeuren.
IT8519907A0 (it) Prodotto farmaceutico cosmetico, in particolare per la cura di acne e seborrea.
DE3774847D1 (de) Trifluorhydroxyaromatische saeure und deren herstellung.
DE3786927D1 (de) Antithrombotische arzneimittel und deren herstellung.
ATE8460T1 (de) Pharmazeutische praeparate und deren herstellung.
ATE94753T1 (de) Arzneimittel, das einen mit einer organischen saeure behandelten und in einem liposom verkapselten hydrophilen wirkstoff enthaelt.
IT8819650A0 (it) Apparecchio per la ginnastica attiva del viso e del collo.
DE3881812D1 (de) Physiologisch aktive substanzen, probestin und prostatin und deren herstellung.
CA992079A (en) Optically active 1,4-benzodiazepines and process for the preparation thereof

Legal Events

Date Code Title Description
8364 No opposition during term of opposition
8339 Ceased/non-payment of the annual fee